These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 33063267

  • 1. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.
    Barbier L, Simoens S, Vulto AG, Huys I.
    BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267
    [Abstract] [Full Text] [Related]

  • 2. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
    Barbier L, Simoens S, Vulto AG, Huys I.
    BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
    [Abstract] [Full Text] [Related]

  • 3. Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking.
    Barbier L, Simoens S, Declerck P, Vulto AG, Huys I.
    Front Pharmacol; 2022 Dec; 13():821616. PubMed ID: 35903323
    [Abstract] [Full Text] [Related]

  • 4. Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging.
    Barbier L, Mbuaki A, Simoens S, Declerck P, Vulto AG, Huys I.
    Front Med (Lausanne); 2022 Dec; 9():820755. PubMed ID: 35355594
    [Abstract] [Full Text] [Related]

  • 5. Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.
    Barbier L, Simoens S, Soontjens C, Claus B, Vulto AG, Huys I.
    Pharmaceuticals (Basel); 2021 May 24; 14(6):. PubMed ID: 34073861
    [Abstract] [Full Text] [Related]

  • 6. Biosimilars in Belgium: a proposal for a more competitive market.
    Moorkens E, Vulto AG, Huys I.
    Acta Clin Belg; 2021 Dec 24; 76(6):441-452. PubMed ID: 32400319
    [Abstract] [Full Text] [Related]

  • 7. Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.
    Mestre-Ferrandiz J, Czech M, Smolen JS, Cornes P, Aapro MS, Danese S, Deitch S, Tyldsley H, Foster W, Shah P, Latymer M, Vulto AG.
    Expert Rev Pharmacoecon Outcomes Res; 2024 Apr 24; 24(4):509-519. PubMed ID: 38284223
    [Abstract] [Full Text] [Related]

  • 8. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J, Skelton JB.
    J Am Pharm Assoc (2003); 2017 Apr 24; 57(5):e15-e27. PubMed ID: 28689708
    [Abstract] [Full Text] [Related]

  • 9. Provider and patient knowledge gaps on biosimilars: insights from surveys.
    Gibofsky A, Evans C, Strand V.
    Am J Manag Care; 2022 Nov 24; 28(12 Suppl):S227-S233. PubMed ID: 36493396
    [Abstract] [Full Text] [Related]

  • 10. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, Claus B, Dimitrova M, Petrova G, Sović-Brkičić L, Slabý J, Šebesta R, Laius O, Karr A, Beck M, Martikainen JE, Selke GW, Spillane S, McCullagh L, Trifirò G, Vella Bonanno P, Mack A, Fogele A, Viksna A, Władysiuk M, Mota-Filipe H, Meshkov D, Kalaba M, Mencej Bedrač S, Fürst J, Zara C, Skiöld P, Magnússon E, Simoens S.
    PLoS One; 2017 Nov 24; 12(12):e0190147. PubMed ID: 29284064
    [Abstract] [Full Text] [Related]

  • 11. Recommendations for Interchangeability in a Growing Biosimilar Market in Latin America.
    Castañeda-Hernández G, Espinoza MA, Pino LE, Rico-Restrepo M, Schiavetti B, Terán E, Azevedo VF.
    Adv Ther; 2024 Dec 24; 41(12):4357-4368. PubMed ID: 39382823
    [Abstract] [Full Text] [Related]

  • 12. To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars.
    Rezk MF, Pieper B.
    Adv Ther; 2018 Jun 24; 35(6):749-753. PubMed ID: 29873005
    [Abstract] [Full Text] [Related]

  • 13. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B, Huys I, Vulto AG, Simoens S.
    BioDrugs; 2020 Apr 24; 34(2):159-170. PubMed ID: 31792843
    [Abstract] [Full Text] [Related]

  • 14. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
    O'Callaghan J, Barry SP, Bermingham M, Morris JM, Griffin BT.
    Eur J Clin Pharmacol; 2019 Jan 24; 75(1):1-11. PubMed ID: 30187103
    [Abstract] [Full Text] [Related]

  • 15. An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain.
    Barcina Lacosta T, Vulto AG, Huys I, Simoens S.
    Front Med (Lausanne); 2022 Jan 24; 9():1029040. PubMed ID: 36703896
    [Abstract] [Full Text] [Related]

  • 16. Healthcare professionals' perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study.
    Aladul MI, Fitzpatrick RW, Chapman SR.
    BMJ Open; 2018 Nov 18; 8(11):e023603. PubMed ID: 30455389
    [Abstract] [Full Text] [Related]

  • 17. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
    Solitano V, D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S.
    Expert Rev Clin Immunol; 2020 Oct 18; 16(10):1019-1028. PubMed ID: 32954893
    [Abstract] [Full Text] [Related]

  • 18. Biosimilars: Practical Considerations for Pharmacists.
    Stevenson JG, Popovian R, Jacobs I, Hurst S, Shane LG.
    Ann Pharmacother; 2017 Jul 18; 51(7):590-602. PubMed ID: 28176529
    [Abstract] [Full Text] [Related]

  • 19. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
    Greene L, Singh RM, Carden MJ, Pardo CO, Lichtenstein GR.
    J Manag Care Spec Pharm; 2019 Aug 18; 25(8):904-912. PubMed ID: 31007119
    [Abstract] [Full Text] [Related]

  • 20. Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective.
    Mestre-Ferrandiz J, Czech M, Smolen JS, Cornes P, Aapro MS, Danese S, Deitch S, Tyldsley H, Foster W, Shah P, Latymer M, Vulto AG.
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb 18; 24(2):237-250. PubMed ID: 38175140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.